569 reports of this reaction
3.3% of all ASFOTASE ALFA reports
#6 most reported adverse reaction
ARTHRALGIA is the #6 most commonly reported adverse reaction for ASFOTASE ALFA, manufactured by Alexion Pharmaceuticals, Inc.. There are 569 FDA adverse event reports linking ASFOTASE ALFA to ARTHRALGIA. This represents approximately 3.3% of all 17,151 adverse event reports for this drug.
Patients taking ASFOTASE ALFA who experience arthralgia should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
ARTHRALGIA is moderately reported among ASFOTASE ALFA users, representing a notable but not dominant share of adverse events.
In addition to arthralgia, the following adverse reactions have been reported for ASFOTASE ALFA:
The following drugs have also been linked to arthralgia in FDA adverse event reports:
ARTHRALGIA has been reported as an adverse event in 569 FDA reports for ASFOTASE ALFA. This does not prove causation, but indicates an association observed in post-market surveillance data.
ARTHRALGIA accounts for approximately 3.3% of all adverse event reports for ASFOTASE ALFA, making it a notable side effect.
If you experience arthralgia while taking ASFOTASE ALFA, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.